Abstract
Introduction: Stereotactic radiotherapy (SABR) is a treatment option for patients with early stage NSCLC who are medically inoperable or who decline surgery. A meta-analysis of 40 SABR studies (4850 patients) showed overall survival at 1, 3 and 5 years of 83.4%, 56.6% and 41.2%, respectively. Most of these data come from large academic centres.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have